Zybrestat (fosbretabulin) / Oncotelic  >>  Phase 2
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zybrestat (fosbretabulin) / Oncotelic
NCT01423149: Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Completed
2
23
US
Combretastatin A-4 Phosphate, CA4P, fosbretabulin
Mateon Therapeutics
Choroidal Neovascularization, Myopia, Degenerative
01/07
01/07
NCT00060242: Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer

Completed
2
26
US
fosbretabulin disodium, Combretastatin A4 phosphate
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Head and Neck Cancer
02/07
01/08
NCT00077103: Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

Terminated
2
4
US
filgrastim, pegfilgrastim, cisplatin, doxorubicin hydrochloride, fosbretabulin disodium, Combretastatin A-4 Phosphate, CA4P, radiation therapy
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Head and Neck Cancer
02/07
12/07
NCT00113438: Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

Completed
2
13
US
Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin, CA4P, fosbretabulin, paclitaxel, carboplatin
Mateon Therapeutics
Cancer, Tumor
02/07
02/07
NCT01023295: Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Completed
2
20
US, RoW
fosbretabulin, combretastatin, CA4P, Saline
Mateon Therapeutics
Polypoidal Choroidal Vasculopathy
08/10
08/10
FALCON, NCT00653939: A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Checkmark P2 data
Nov 2011 - Nov 2011: P2 data
Checkmark P2 data-FALCON
Nov 2011 - Nov 2011: P2 data-FALCON
Checkmark P2 data - 1st line, stg IIIB/IV, FALCON
More
Completed
2
63
US
Fosbretabulin, Combretastatin A4 Phosphate, Zybrestat, CA4P, Carboplatin, Paraplatin, Paclitaxel, Taxol, Bevacizumab, Avastin
Mateon Therapeutics
Tumors
07/11
10/11
NCT02132468: A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Completed
2
18
US
fosbretabulin tromethamine, fosbretabulin, combretastatin A4-phosphate, CA4P
Mateon Therapeutics
Neuroendocrine Tumors
06/16
08/16
NCT02279602: Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Completed
2
7
US
fosbretabulin, CA4P, combretastatin A-4 phosphate
Mateon Therapeutics
Neuroendocrine Tumors
08/16
08/16
NCT01305213: Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Checkmark OC (GOG-01861) trial in ovarian cancer
Oct 2016 - Oct 2016: OC (GOG-01861) trial in ovarian cancer
Checkmark SGO 2015
Mar 2015 - Mar 2015: SGO 2015
Checkmark Zybrestat in combination with Avastin for recurrent ovarian cancer
More
Completed
2
107
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar SCT501, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Fosbretabulin Tromethamine, CA4P, Zybrestat, Laboratory Biomarker Analysis
National Cancer Institute (NCI), NRG Oncology
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
08/16
11/16
PAZOFOS, NCT02055690 / 2013-005471-40: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

Checkmark Initiation of P2 trial (N=120) with Zybrestat in ovarian cancer
Sep 2014 - Sep 2014: Initiation of P2 trial (N=120) with Zybrestat in ovarian cancer
Terminated
2
21
Europe
Pazopanib, Votrient, EU/1/10/628/001, EU/1/10/628/002, Fosbretabulin, Fosbretabulin tromethamine
The Christie NHS Foundation Trust, Novartis, Mateon Therapeutics, East and North Hertfordshire NHS Trust
Ovarian Neoplasms, Neoplasms, Ovarian, Ovarian Cancer
11/17
11/17
NCT01570790: Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

Completed
1/2
8
US
Combretastatin A-4 phosphate, fosbretabulin disodium, Combretastatin A-4 Phosphate
Johns Hopkins University
Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV, Choroidal Neovascularization
06/05
06/05

Download Options